EVATANEPAG SODIUM

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C25H27N2O5S.Na
Molecular Weight	490.547
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].CC(C)(C)C1=CC=C(CN(CC2=CC=CC(OCC([O-])=O)=C2)S(=O)(=O)C3=CN=CC=C3)C=C1

InChI

InChIKey=SVNBMCJEDANCKY-UHFFFAOYSA-M

InChI=1S/C25H28N2O5S.Na/c1-25(2,3)21-11-9-19(10-12-21)16-27(33(30,31)23-8-5-13-26-15-23)17-20-6-4-7-22(14-20)32-18-24(28)29;/h4-15H,16-18H2,1-3H3,(H,28,29);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula	C25H27N2O5S
Molecular Weight	467.557
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Na
Molecular Weight	22.98976928
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19250823 | https://www.ncbi.nlm.nih.gov/pubmed/14606517 | https://adisinsight.springer.com/drugs/800018231

Evatanepag (CP-533,536) is a prostaglandin E2 EP2 receptor agonist. It stimulates new bone formation on trabecular, endocortical, and periosteal surfaces and enhances fracture healing. Evatanepag was under development with Pfizer as a bone formation stimulant for therapeutic use in the healing of fractures.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Prostanoid EP2 receptor 20 Target ID: CHEMBL1881 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24279689	Agonist 2752		5.0 nM [EC50]

PubMed

Title	Date	PubMed
Discovery of CP-533536: an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation.	2009-04-01	19250823
CYP2C8- and CYP3A-mediated C-demethylation of (3-{[(4-tert-butylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid (CP-533,536), an EP2 receptor-selective prostaglandin E2 agonist: characterization of metabolites by high-resolution liquid chromatography-tandem mass spectrometry and liquid chromatography/mass spectrometry-nuclear magnetic resonance.	2008-10	18653741
In vitro pharmacological characterization of CJ-042794, a novel, potent, and selective prostaglandin EP(4) receptor antagonist.	2008-01-16	18155068

Patents

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:06:12 GMT 2025` Edited by `admin` on `Mon Mar 31 18:06:12 GMT 2025`
Record UNII	U6GMO13KCQ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

EVATANEPAG SODIUM

Official Name

English

C-533,536-02

Preferred Name

English

CP-533,536-02

Code

English

Sodium 2-(3-{[{[4-(1,1-dimethylethyl)phenyl]methyl}(pyridin-3-ylsulfonyl)amino]methyl}phenoxy)acetate

Systematic Name

English

C-533536-02

Code

English

CP-533536-02

Code

English

EVATANEPAG SODIUM [USAN]

Common Name

English

ACETIC ACID, 2-(3-((((4-(1,1-DIMETHYLETHYL)PHENYL)METHYL)(3-PYRIDINYLSULFONYL)AMINO)METHYL)PHENOXY)-, SODIUM SALT (1:1)

Systematic Name

English

C-53353602

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C78568